Binding Site Case Study
For 30 years, Binding Site has specialised in delivering innovative medical solutions that improve the diagnosis and management of blood cancers and immune system disorders. Headquartered in Greater Birmingham’s Medical Quarter, the company operates on a global scale, with nine international bases and 90% of its products sold overseas.
The £80 million company has grown from initially employing three, to now employing 500 people at its Birmingham HQ, research centre and manufacturing base. Currently witnessing double-digit annual business growth, Binding Site has recently achieved a Queen’s award for enterprise, in the category of international trade, the highest accolade for business success.
The company has opted to stay and build on this success in Greater Birmingham, taking advantage of the area’s strong links with the University of Birmingham and the Queen Elizabeth Hospital, as well as the region’s central UK location and well-connected transport links.
Binding Site Non-Executive Director and Former CEO, Charles de Rohan said:
“This is a city of excellence – not just in medicine, but across the board. Birmingham is a tremendous place for businesses to locate.”
“Binding Site invests heavily in research and development and therefore hugely benefits from local institutions like the University of Birmingham. Our R&D department comprises 70 people, most of who originate from in and around Birmingham. The talent pool on offer here is vast – half of the people that work here are from manufacturing-related backgrounds and are very highly-skilled and qualified. Each year, we also take 20 local students into the company on placements and they’re able to add a great deal of value to our company”.
“Unique to Binding Site is the Freelite® assay. Freelite is a polyclonal antibody-based test, specifically designed to accurately and precisely measure monoclonal free light chains in blood. Free light chains are produced in a variety of haematological cancers including Multiple Myeloma. The introduction of the Freelite test into clinical laboratories in 2001 changed the paradigm for patients – whereby the use of the tests has made a major contribution to a better understanding of these disease conditions and their outcome.”
Now exporting six million diagnostic tests a year across 90 countries globally, Binding Site is seeing increasing investor interest, as businesses look to join the company as it becomes a global leader in the medical diagnostics industry.
Read more about life sciences and contact us to find out more about relocating in the West Midlands.
Find out more about Binding Site on their website.